Currently, treatments for breast cancer are based on three broad classes: estrogen receptor α-positive or progesterone receptor-positive breast cancer, human epidermal growth factor receptor 2-enriched breast cancer, and triple-negative breast cancer that expresses none of these three receptors (4). Here, ERBB2 is linked to breast cancer.